Posted by Michael Wonder on 04 Feb 2019
Fresenius Kabi receives positive CHMP opinion for MSB11022, a biosimilar candidate of adalimumab
1 February 2019 - Fresenius Kabi announced today that the CHMP of the EMA has issued a positive opinion, recommending marketing authorisation for MSB11022, a biosimilar candidate of Humira (adalimumab).
The European Commission will now decide on the approval of MSB11022 which is expected in Q2/2019.
